
|Videos|April 29, 2019
The Future of Migraine Prevention and Treatment
Advertisement
Episodes in this series

Transcript:
Advertisement
Related to this article

An oral SERD plus everolimus cut the risk of progression or death by 62% in ESR1-mutated advanced breast cancer.

New York hepatitis B experts say screening gaps and weekly monitoring demands could limit who benefits from the first functional cure therapy.

Phase 3 OASIZ-301 data at ACR 2026 show dazodalibep lowered systemic activity in Sjögren disease, with dryness gains at the every-4-weeks dose.

San Francisco experts say earlier IgA nephropathy and FSGS detection depends on primary care education and care coordinators.

Cardiologists and pharmacy leaders explained how team-based clinics and standardized paperwork are speeding obstructive HCM treatment.

The FDA has approved secukinumab for PMR after the REPLENISH trial showed doubled sustained remission and lower steroid use vs a steroid taper alone.

Earlier MASH fibrosis detection is more urgent now that treatments exist, and automating FIB-4 in EHRs could help primary care, says Rohit Loomba, MD.
Advertisement
Advertisement
Trending on AJMC
1
FDA Grants Accelerated Approval to Neladalkib for Previously Treated ALK-Positive NSCLC
2
Emerging Threats to Cell and Gene Therapy Access
3
GLP-1s Alone Won't Solve Obesity, JAMA Summit Report Says
4
Atopic Dermatitis Escalation Stalls on Payer Rules, Thin Tracking
5












